Precigen, Inc. (NASDAQ:PGEN) Shares Bought by Geode Capital Management LLC

Geode Capital Management LLC grew its holdings in Precigen, Inc. (NASDAQ:PGEN) by 4.8% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,246,508 shares of the biotechnology company’s stock after purchasing an additional 149,829 shares during the quarter. Geode Capital Management LLC owned approximately 1.28% of Precigen worth $3,075,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the business. Iridian Asset Management LLC CT lifted its holdings in Precigen by 82.5% in the 3rd quarter. Iridian Asset Management LLC CT now owns 3,775,960 shares of the biotechnology company’s stock valued at $3,576,000 after purchasing an additional 1,706,815 shares in the last quarter. Renaissance Technologies LLC raised its position in shares of Precigen by 12.4% in the second quarter. Renaissance Technologies LLC now owns 1,182,690 shares of the biotechnology company’s stock valued at $1,869,000 after buying an additional 130,500 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in shares of Precigen by 11.6% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,222,850 shares of the biotechnology company’s stock valued at $1,158,000 after buying an additional 127,467 shares during the period. HighTower Advisors LLC boosted its position in Precigen by 186.8% during the third quarter. HighTower Advisors LLC now owns 192,144 shares of the biotechnology company’s stock worth $179,000 after acquiring an additional 125,145 shares during the last quarter. Finally, Barclays PLC grew its stake in Precigen by 190.4% in the 3rd quarter. Barclays PLC now owns 189,353 shares of the biotechnology company’s stock worth $179,000 after acquiring an additional 124,141 shares during the period. 33.51% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “buy” rating and set a $4.00 price target on shares of Precigen in a research note on Friday, November 15th. Two investment analysts have rated the stock with a sell rating and four have given a buy rating to the company’s stock. According to MarketBeat, Precigen has an average rating of “Hold” and a consensus price target of $7.00.

Precigen Stock Up 5.8 %

Shares of NASDAQ PGEN opened at $1.27 on Tuesday. The stock has a market capitalization of $371.94 million, a P/E ratio of -2.31 and a beta of 1.65. The stock’s 50 day moving average price is $0.86 and its two-hundred day moving average price is $1.09. Precigen, Inc. has a 52-week low of $0.65 and a 52-week high of $1.93.

Precigen Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.